The tumor suppressor annexin A10 is a novel component of nuclear paraspeckles
- 1.1k Downloads
Annexin A10 is the latest identified member of the annexin family of Ca2+- and phospholipid-binding proteins. In previous studies, downregulation of annexin A10 was correlated with dedifferentiation, invasion, and tumor progression, pointing to a possible tumor suppressor role. However, the biochemical characteristics and functions of annexin A10 remain unknown. We show that annexin A10 displays biochemical characteristics atypical for an annexin, indicating a Ca2+- and membrane-binding-independent function. Annexin A10 co-localizes with the mRNA-binding proteins SFPQ and PSPC1 at paraspeckles, an only recently discovered nuclear body, and decreases paraspeckle numbers when overexpressed in HeLa cells. In addition, annexin A10 relocates to dark perinucleolar caps upon transcriptional inhibition of RNA polymerase II. We mapped the cap-binding function of annexin A10 to the proximal part of the core domain, which is missing in the short isoform of annexin A10, and show its independence from the remaining functional type II Ca2+-binding site. In contrast to this, paraspeckle recruitment required additional core regions and was negatively affected by the mutation of the last type II Ca2+-binding site. Additionally, we show that overexpression of annexin A10 in HeLa cells increases their sensitivity to apoptosis and reduces colony formation. The identification of unique nuclear and biochemical characteristics of annexin A10 points towards its membrane-independent role in paraspeckle-associated mRNA regulation or processing.
KeywordsParaspeckles Nucleolar caps Annexin A10 Apoptosis
We thank Annette Janning for technical assistance. Rabbit polyclonal anti-annexin A10 antibody was generously provided by Reginald Morgan (Department of Biochemistry and Molecular Biology, University of Oviedo, Spain). This work was supported by grants from the Interdisciplinary Clinical Research Centre of the University of Münster (IZKF, RE2/017/10) and the German Research Foundation (DFG, RE2611/2-1, SFB 629/A1) to V.G. and U.R.
Conflict of interest
The authors declare no competing financial interests.
- 19.Hayes MJ, Merrifield CJ, Shao D, Ayala-Sanmartin J, Schorey CD, Levine TP, Proust J, Curran J, Bailly M, Moss SE (2004) Annexin 2 binding to phosphatidylinositol 4,5-bisphosphate on endocytic vesicles is regulated by the stress response pathway. J Biol Chem 279:14157–14164PubMedCentralPubMedCrossRefGoogle Scholar
- 31.Lopez-Pedrera C, Villalba JM, Siendones E, Barbarroja N, Gomez-Diaz C, Rodriguez-Ariza A, Buendia P, Torres A, Velasco F (2006) Proteomic analysis of acute myeloid leukemia: identification of potential early biomarkers and therapeutic targets. Proteomics 6(Suppl 1):S293–S299PubMedCrossRefGoogle Scholar
- 36.Munksgaard PP, Mansilla F, Brems Eskildsen AS, Fristrup N, Birkenkamp-Demtroder K, Ulhoi BP, Borre M, Agerbaek M, Hermann GG, Orntoft TF, Dyrskjot L (2011) Low ANXA10 expression is associated with disease aggressiveness in bladder cancer. Br J Cancer 105:1379–1387PubMedCentralPubMedCrossRefGoogle Scholar
- 44.Peng SY, Ou YH, Chen WJ, Li HY, Liu SH, Pan HW, Lai PL, Jeng YM, Chen DC, Hsu HC (2005) Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. Int J Oncol 26:1053–1061PubMedGoogle Scholar
- 48.Raynal P, van Bergen en Henegouwen PM, Hullin F, Ragab-Thomas JM, Fauvel J, Verkleij A and Chap H (1992) Morphological and biochemical evidence for partial nuclear localization of annexin 1 in endothelial cells. Biochem Biophys Res Commun 186:432-439Google Scholar